ASLAN Pharmaceuticals Limited

Equities

ASLN

US04522R2004

Biotechnology & Medical Research

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.6152 USD -2.50% Intraday chart for ASLAN Pharmaceuticals Limited -11.49% +17.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Thursday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading MT
HC Wainwright Cuts ASLAN Pharmaceuticals Price Target to $9 From $17, Maintains Buy Rating MT
ADRs Slump; Hello Group Declines 22% DJ
Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading MT
Piper Sandler Cuts ASLAN Pharmaceuticals' Price Target to $10 From $15, Maintains Overweight Rating MT
ADRs End Higher, ATRenew Inc. Climbs 26.9% DJ
Asian Equities Traded in the US as American Depositary Receipts Rally in Tuesday Trading MT
ADRs Close Lower, Immuron Ltd. Declines 17.1% DJ
Bank Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients CI
ASLAN Pharmaceuticals Limited Announces New Translational Data on Eblasakimab in COPD CI
ASLAN Pharmaceuticals Limited Appoints Ramaswamy Krishnan and Reynold Panettieri as Scientific Advisors CI
Asian Equities Traded in US as ADRs Edge Higher Monday Afternoon MT
ADRs End Higher; Hesai Group Climbs 20% DJ
Asian Equities Traded in the US as American Depositary Receipts Surge Higher in Friday Trading, Led by Tech, Bank Stocks MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
ADRs Close Lower; Ambow Education Holding Ltd. Declines 23.3% DJ
Bank, Auto Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Wednesday MT
Chart ASLAN Pharmaceuticals Limited
More charts
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6152 USD
Average target price
27.5 USD
Spread / Average Target
+4,370.09%
Consensus
  1. Stock
  2. Equities
  3. Stock ASLAN Pharmaceuticals Limited - Nasdaq
  4. News ASLAN Pharmaceuticals Limited
  5. ASLAN Pharmaceuticals : Jefferies & Co Initiates Coverage on ASLAN Pharmaceuticals With Buy Rating, $8 Price Target